DelveInsight’s, “Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diffuse Intrinsic Pontine Glioma Research. Learn more about our innovative pipeline today! @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report

• June 2024:- Nationwide Children’s Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
• June 2024:- Pfizer- A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1).
• DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
• The leading Diffuse Intrinsic Pontine Glioma Companies such as Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
• Promising Diffuse Intrinsic Pontine Glioma Therapies such as Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.

Stay informed about the cutting-edge advancements in Diffuse Intrinsic Pontine Glioma Treatments. Download for updates and be a part of the revolution in disease care @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile

• MTX 110: Midatech

MTX110 is a water‐soluble form of panobinostat free base, achieved through complexation with hydroxypropyl‐β‐ cyclodextrin (HPBCD) that enables convection‐enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non‐selective histone deacetylase inhibitor (pan‐HDAC inhibitor). Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma. MTX110 is delivered directly into and around the patient’s tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood‐brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient‐derived DIPG cell lines.

• Paxalisib: Kazia Therapeutics

Paxalisib (originally GDC-0084) was invented by Genentech, Inc (South San Francisco, CA), the most successful developer of new cancer medicines in the world. Kazia entered into a worldwide exclusive license agreement with Genentech in October 2016. Genentech designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The distinguishing feature of paxalisib is its ability to cross the blood-brain barrier (BBB). Ordinarily, the BBB prevents many drugs from reaching brain tissue, and is a challenge in the treatment of any disease in the central nervous system. Paxalisib has been designed to cross the BBB, and a wealth of experimental data shows that it does so very successfully. This feature of paxalisib is almost unique in this class of medicines and differentiates it from the approved products in the PI3K inhibitor class.

Learn more about Diffuse Intrinsic Pontine Glioma Drugs opportunities in our groundbreaking H Diffuse Intrinsic Pontine Glioma Research and development projects @ Diffuse Intrinsic Pontine Glioma Unmet Needs

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Diffuse Intrinsic Pontine Glioma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report

• Coverage- Global
• Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
• Diffuse Intrinsic Pontine Glioma Therapies- Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Diffuse Intrinsic Pontine Glioma Pipeline on our website @ Diffuse Intrinsic Pontine Glioma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Diffuse Intrinsic Pontine Glioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diffuse Intrinsic Pontine Glioma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. MTX 110: Midatech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diffuse Intrinsic Pontine Glioma Key Companies
21. Diffuse Intrinsic Pontine Glioma Key Products
22. Diffuse Intrinsic Pontine Glioma- Unmet Needs
23. Diffuse Intrinsic Pontine Glioma- Market Drivers and Barriers
24. Diffuse Intrinsic Pontine Glioma- Future Perspectives and Conclusion
25. Diffuse Intrinsic Pontine Glioma Analyst Views
26. Diffuse Intrinsic Pontine Glioma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/